Apexbio Technology LLC Everolimus (RAD001) 159351-69-6 10mM (in 1mL DMSO)

Supplier:  Apexbio Technology LLC A81695.1

Everolimus (RAD001) is an orally bioavailable small-molecule inhibitor targeting mammalian target of rapamycin (mTOR) an integral serine/threonine kinase regulating cell proliferation metabolism and survival within the PI3K/Akt pathway Everolimus binds intracellularly to the immunophilin FKBP12 the resulting complex subsequently interacts directly with mTOR inhibiting its kinase activity thereby reducing downstream phosphorylation of S6 kinase 1 (S6K1) and the eukaryotic initiation factor 4E-binding protein (4EBP) Functionally Everolimus exerts immunosuppressive properties used clinically to prevent organ transplant rejection and demonstrates antitumor activity against several malignancies including renal cell carcinoma and basal cell carcinoma Commonly utilized in cancer research Everolimus inhibits mTOR with IC50 values reported in the low nanomolar range ( 1 3 nM)

Catalog No. 50-000-61574